Civic Intelligence

Transcelerate Biopharma Inc

990 • Fiscal year 2012 • EIN 46-0886344

Jan 01, 2012 to Dec 31, 2012

Organization ProfileWWW.TRANSCELERATEBIOPHARMAINC.COM
West Conshohocken, PA
Siviq Scores

Precomputed percentiles for this filing year versus similar nonprofits in the same peer cohort.

Liabilities / Assets

96th percentile

0.97x

Higher debt load relative to assets than 96% of similar nonprofits.

2012 filings • 501(c)6 • $5M-$10M nonprofits • Source year 2012

Liabilities / Revenue

90th percentile

1.00x

Higher debt load relative to revenue than 90% of similar nonprofits.

2012 filings • 501(c)6 • $5M-$10M nonprofits • Source year 2012

Net Margin

47th percentile

3.1%

Higher net margin than 47% of similar nonprofits.

2012 filings • 501(c)6 • $5M-$10M nonprofits • Source year 2012

Top Officer Pay

Score unavailable

No value available

This filing does not contain officer compensation rows.

Source year 2012

Asset Growth

Score unavailable

No value available

No earlier valid filing was available within the previous three public years.

Source year 2012

Revenue Growth

Score unavailable

No value available

No earlier valid filing was available within the previous three public years.

Source year 2012

Balance Sheet
Liabilities / Assets96th percentile

Assets

$5,857,436

No earlier filing loaded for comparison.

Net Assets

$178,632

No earlier filing loaded for comparison.

Liabilities

$5,678,804

No earlier filing loaded for comparison.

Revenue And Expenses
Liabilities / Revenue90th percentileNet Margin47th percentile

Revenue

$5,672,849

No earlier filing loaded for comparison.

Expenses

$5,494,217

No earlier filing loaded for comparison.

Net Income

$178,632

No earlier filing loaded for comparison.

Historical Trend

Balance Sheet Trend

Asset GrowthScore unavailable

The highlighted filing sits inside the broader history for assets, liabilities, and net assets.

$60M$40M$20M$0Assets 2012: $5,857,436Liabilities 2012: $5,678,804Net Assets 2012: $178,6322012Assets 2013: $9,075,300Liabilities 2013: $1,902,607Net Assets 2013: $7,172,6932013Assets 2014: $34,898,547Liabilities 2014: $24,786,391Net Assets 2014: $10,112,1562014Assets 2015: $43,370,074Liabilities 2015: $24,062,150Net Assets 2015: $19,307,9242015Assets 2016: $44,721,813Liabilities 2016: $28,468,410Net Assets 2016: $16,253,4032016Assets 2017: $43,979,845Liabilities 2017: $30,831,873Net Assets 2017: $13,147,9722017Assets 2018: $38,632,750Liabilities 2018: $31,059,509Net Assets 2018: $7,573,2412018Assets 2019: $45,613,199Liabilities 2019: $36,755,773Net Assets 2019: $8,857,4262019Assets 2020: $49,374,410Liabilities 2020: $36,650,129Net Assets 2020: $12,724,2812020Assets 2021: $50,373,384Liabilities 2021: $39,738,784Net Assets 2021: $10,634,6002021Assets 2022: $48,482,660Liabilities 2022: $38,508,812Net Assets 2022: $9,973,8482022Assets 2023: $48,107,662Liabilities 2023: $36,490,338Net Assets 2023: $11,617,3242023

Highlighted filing

2012

Assets$5,857,436
Liabilities$5,678,804
Net Assets$178,632
Open 2012 Filing

Operations Trend

Revenue GrowthScore unavailable

Revenue, expenses, and net income across loaded years, with this filing highlighted.

$40M$30M$20M$10M$0-$10MRevenue 2012: $5,672,849Expenses 2012: $5,494,217Net Income 2012: $178,6322012Revenue 2013: $13,643,765Expenses 2013: $6,823,303Net Income 2013: $6,820,4622013Revenue 2014: $15,293,388Expenses 2014: $11,780,323Net Income 2014: $3,513,0652014Revenue 2015: $25,465,264Expenses 2015: $16,269,496Net Income 2015: $9,195,7682015Revenue 2016: $20,679,184Expenses 2016: $23,733,704Net Income 2016: -$3,054,5202016Revenue 2017: $26,172,580Expenses 2017: $29,275,313Net Income 2017: -$3,102,7332017Revenue 2018: $25,318,445Expenses 2018: $30,891,037Net Income 2018: -$5,572,5922018Revenue 2019: $27,979,345Expenses 2019: $26,700,072Net Income 2019: $1,279,2732019Revenue 2020: $31,974,894Expenses 2020: $28,107,965Net Income 2020: $3,866,9292020Revenue 2021: $31,090,660Expenses 2021: $33,180,341Net Income 2021: -$2,089,6812021Revenue 2022: $33,600,302Expenses 2022: $34,262,372Net Income 2022: -$662,0702022Revenue 2023: $34,168,812Expenses 2023: $32,521,149Net Income 2023: $1,647,6632023

Highlighted filing

2012

Revenue$5,672,849
Expenses$5,494,217
Net Income$178,632
Open 2012 Filing
Filing Detail Status

This 2012 filing currently has summary financial data only. Detailed schedules, leadership, and program rows are not available for this filing yet.

View Latest Detailed Filing (2024)
Jump To
Filing Snapshot
Filing Period
Jan 1, 2012 to Dec 31, 2012
Mission and Program Overview

Mission

Transcelerate biopharma inc. Is dedicated to improving the health of people around the world by accelerating and enhancing the research and development (r&d) of innovative new therapies.the organization's mission is to collaborate across the global biopharmaceutical r&d community to identify, design and facilitate implementation of solutions designed to drive the efficient, effective and high quality delivery of new medicines. Transcelerate evolved from conversations at various forums for executive r&d leadership to discuss current issues facing the industry, and examine solutions for addressing common challenges.membership in transcelerate is open to biopharmaceutical companies with research & development operations.

Document Assets

No mirrored PDF or thumbnail assets are attached yet.

Filings

Displayed year

2012 • Form 990Summary only. Only limited summary data is available for this year.

Open filing
Assets
$5,857,436
Liabilities
$5,678,804
Net assets
$178,632
Revenue
$5,672,849
Expenses
$5,494,217
Net income
$178,632
Balance SheetOperations
YearAssetsLiabilitiesNet AssetsRevenueExpensesNet Income
2023Summary only. Only limited summary data is available for this year.$48.1$36.5$11.6$34.2$32.5$1.65
2022XML pending. An XML filing is linked for this year, but detailed extraction is still pending.$48.5$38.5$9.97$33.6$34.3$0.66
2021Summary only. Only limited summary data is available for this year.$50.4$39.7$10.6$31.1$33.2$2.09
2020XML pending. An XML filing is linked for this year, but detailed extraction is still pending.$49.4$36.7$12.7$32.0$28.1$3.87
2019XML pending. An XML filing is linked for this year, but detailed extraction is still pending.$45.6$36.8$8.86$28.0$26.7$1.28
2018XML pending. An XML filing is linked for this year, but detailed extraction is still pending.$38.6$31.1$7.57$25.3$30.9$5.57
2017XML pending. An XML filing is linked for this year, but detailed extraction is still pending.$44.0$30.8$13.1$26.2$29.3$3.10
2016Facts available. Structured filing facts are available, but richer extracted sections are limited.$44.7$28.5$16.3$20.7$23.7$3.05
2015Summary only. Only limited summary data is available for this year.$43.4$24.1$19.3$25.5$16.3$9.20
2014Detailed filing. Detailed filing data is available for this year.$34.9$24.8$10.1$15.3$11.8$3.51
2013Detailed filing. Detailed filing data is available for this year.$9.08$1.90$7.17$13.6$6.82$6.82
2012Summary only. Only limited summary data is available for this year.$5.86$5.68$0.18$5.67$5.49$0.18